<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Clin J Gastroenterol</journal-id><journal-title-group><journal-title>Clinical Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1865-7257</issn><issn pub-type="epub">1865-7265</issn><publisher><publisher-name>Springer Nature Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39446307</article-id><article-id pub-id-type="pmc">PMC11785621</article-id>
<article-id pub-id-type="publisher-id">2044</article-id><article-id pub-id-type="doi">10.1007/s12328-024-02044-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Aiko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1887-1096</contrib-id><name><surname>Kawaoka</surname><given-names>Tomokazu</given-names></name><address><email>kawaokatomo@hiroshima-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Uchikawa</surname><given-names>Shinsuke</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fujino</surname><given-names>Hatsue</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ono</surname><given-names>Atsushi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Murakami</surname><given-names>Eisuke</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hayes</surname><given-names>Clair Nelson</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Miki</surname><given-names>Daiki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tsuge</surname><given-names>Masataka</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oka</surname><given-names>Shiro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03t78wx29</institution-id><institution-id institution-id-type="GRID">grid.257022.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 8711 3200</institution-id><institution>Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, </institution><institution>Hiroshima University, </institution></institution-wrap>1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038dg9e86</institution-id><institution-id institution-id-type="GRID">grid.470097.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0618 7953</institution-id><institution>Liver Center, </institution><institution>Hiroshima University Hospital, </institution></institution-wrap>Hiroshima, Japan </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>18</volume><issue>1</issue><fpage>107</fpage><lpage>113</lpage><history><date date-type="received"><day>27</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>9</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">A 58-year-old man visited an orthopedic clinic complaining of pain in his right lower back and numbness in his lower limbs for one month. Imaging tests revealed a tumorous lesion from the left side of the second lumbar vertebra to the paraspinal muscles. CT-guided biopsy of the tumor was performed, and immunostaining results diagnosed hepatocellular carcinoma (HCC). Although the liver showed signs of chronic liver damage, no primary tumor was found within the liver or in other organs. Blood tests showed negative hepatitis virus markers for both HBV and HCV. The tumor markers AFP, AFP-L3, and DCP were high. Because he developed spinal cord compression syndrome due to a lumbar tumor, radiation therapy and denosumab administration were performed. Subsequently, systemic therapy with durvalumab plus tremelimumab was started. In the year following the start of treatment, the tumor has shrunk, and no new lesions have been observed. Tumor markers have also decreased. We have experienced a case of HCC in the lumbar spine without a primary tumor in the liver. This is a very rare case, and the combination therapy with durvalumab and tremelimumab resulted in a complete response, which we consider to be a valuable case.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatocellular carcinoma</kwd><kwd>Radiation therapy</kwd><kwd>Durvalumab</kwd><kwd>Tremelimumab</kwd></kwd-group><funding-group><award-group><funding-source><institution>Hiroshima University</institution></funding-source></award-group><open-access><p>Open Access funding provided by Hiroshima University.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Japanese Society of Gastroenterology 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par17">HCC is the sixth most common cancer worldwide and the third deadliest [<xref ref-type="bibr" rid="CR1">1</xref>], and patients with hepatocellular carcinoma are frequently treated. Hepatocellular carcinoma originates in the liver, but there are rare types of HCC that arise outside the liver. These may originate as ectopic hepatocellular carcinoma, hepatoid adenocarcinoma, or spontaneous necrosis of intrahepatic hepatocellular carcinoma. Treatment of hepatocellular carcinoma includes liver resection or liver transplantation, local therapy, chemoembolization, and systemic drug therapy with durvalumab and tremelimumab or atezolizumab and bevacizumab, with immune checkpoint inhibitors being the first-line systemic drug therapy. In recent years, it has become known that the combination of radiation therapy and immune checkpoint inhibition can enhance therapeutic efficacy [<xref ref-type="bibr" rid="CR2">2</xref>]. In this report, we describe a case of a very rare HCC of unknown primary that was successfully treated with radiotherapy and an immune checkpoint inhibitor (ICI).</p></sec><sec id="Sec2"><title>Case report</title><p id="Par18">The patient is a 58-year-old male on hemodialysis attending a local physician for type 2 diabetes mellitus and end-stage renal failure. In December 202X, he visited an orthopedic surgeon because he was aware of right lumbar pain and numbness in his lower limbs. Lumbar spine MRI showed a 4&#x000a0;cm neoplastic lesion from the left side of the second lumbar vertebral body to the paraspinal muscles. The patient was referred to our hospital in February 202X&#x02009;+&#x02009;1 for close examination of lumbar spine tumor. The results of CT-guided aspiration cytology showed Class V, and immunostaining showed Hepatocyte-positive, Glypican-3-negative, Arginase1-positive, and S100-negative histology, leading to the diagnosis of HCC (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Histopathological features of the tumor located in the second lumbar vertebrae. <bold>a</bold> Hematoxylin&#x02013;eosin staining (HE) (&#x000d7;&#x02009;400). <bold>b</bold> Hepatocyte marker is positive in cytoplasm (&#x000d7;&#x02009;200). <bold>c</bold> Glypican3 marker is negative in cytoplasm (&#x000d7;&#x02009;200). <bold>d</bold> Arginase1 marker is positive in the cytoplasm (&#x000d7;&#x02009;200)</p></caption><graphic xlink:href="12328_2024_2044_Fig1_HTML" id="MO1"/></fig></p><p id="Par19">Contrast-enhanced CT and MRI were performed to search for the primary tumor. The liver showed evidence of chronic liver damage, but no primary tumor was found in the liver or other organs, and no obvious primary tumor was noted on upper and lower gastrointestinal endoscopy.</p><p id="Par20">PET-CT showed an accumulation of SUV max 8.8 only in the lumbar spine tumor area. Based on imaging and pathology results, he was diagnosed as cT0N0M1, cStage IVB, BCLC stage C HCC.</p><p id="Par21">Blood tests at the initial visit showed T-Bil 0.8&#x000a0;mg/dL, AST 19U/L, ALT 21U/L, Alb 3.8&#x000a0;g/dL, PT activity 96%, and liver function was preserved. He was also HBsAg negative, HBsAb negative, HBcAb negative, HCVAb negative, anti-nuclear antibody negative, anti-mitochondrial antibody negative, and his background liver was NBNC. Tumor markers included elevated AFP 57.2&#x000a0;ng/mL, AFP-L3 11.5%, DCP 261mAU/mL (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Laboratory examinations</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Complete blood cell count</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;WBC</td><td align="left">9410</td><td align="left">/&#x003bc;L</td></tr><tr><td align="left">&#x000a0;Neutrophil</td><td align="left">66.4</td><td align="left">%</td></tr><tr><td align="left">&#x000a0;Lymphocytes</td><td align="left">19</td><td align="left">%</td></tr><tr><td align="left">&#x000a0;Monocytes</td><td align="left">8.8</td><td align="left">%</td></tr><tr><td align="left">&#x000a0;Eosinophil</td><td align="left">5.3</td><td align="left">%</td></tr><tr><td align="left">&#x000a0;Basophil</td><td align="left">0.5</td><td align="left">%</td></tr><tr><td align="left">&#x000a0;RBC</td><td align="left">4.43&#x02009;&#x000d7;&#x02009;10<sup>4</sup></td><td align="left">/&#x003bc;L</td></tr><tr><td align="left">&#x000a0;Hb</td><td align="left">12.5</td><td align="left">g/dL</td></tr><tr><td align="left">&#x000a0;Ht</td><td align="left">39.6</td><td align="left">%</td></tr><tr><td align="left">&#x000a0;Plt</td><td align="left">146&#x02009;&#x000d7;&#x02009;10<sup>3</sup></td><td align="left">/&#x003bc;L</td></tr><tr><td align="left">Blood coagulation test</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;PT activity</td><td align="left">96</td><td align="left">%</td></tr><tr><td align="left">&#x000a0;PT-INR</td><td align="left">1.01</td><td align="left"/></tr><tr><td align="left">Blood chemistry</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;T-Bil</td><td align="left">0.8</td><td align="left">mg/dL</td></tr><tr><td align="left">&#x000a0;AST</td><td align="left">19</td><td align="left">IU/L</td></tr><tr><td align="left">&#x000a0;ALT</td><td align="left">21</td><td align="left">IU/L</td></tr><tr><td align="left">&#x000a0;LDH</td><td align="left">190</td><td align="left">IU/L</td></tr><tr><td align="left">&#x000a0;ALP</td><td align="left">100</td><td align="left">IU/L</td></tr><tr><td align="left">&#x000a0;&#x003b3;-GTP</td><td align="left">46</td><td align="left">IU/L</td></tr><tr><td align="left">&#x000a0;Na</td><td align="left">137</td><td align="left">mEq/L</td></tr><tr><td align="left">&#x000a0;K</td><td align="left">4.1</td><td align="left">mEq/L</td></tr><tr><td align="left">&#x000a0;Cl</td><td align="left">100</td><td align="left">mEq/L</td></tr><tr><td align="left">&#x000a0;TP</td><td align="left">7.4</td><td align="left">g/dL</td></tr><tr><td align="left">&#x000a0;Alb</td><td align="left">3.8</td><td align="left">g/dL</td></tr><tr><td align="left">&#x000a0;BUN</td><td align="left">31.6</td><td align="left">mg/dL</td></tr><tr><td align="left">&#x000a0;Cr</td><td align="left">10.2</td><td align="left">mg/dL</td></tr><tr><td align="left">&#x000a0;CRP</td><td align="left">0.07</td><td align="left">mg/dL</td></tr><tr><td align="left">&#x000a0;NH3</td><td align="left">29</td><td align="left">&#x003bc;mol/L</td></tr><tr><td align="left">&#x000a0;HbA1c</td><td align="left">6.2</td><td align="left">%</td></tr><tr><td align="left">Viral markers</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;HBs antigen</td><td align="left">(&#x02013;)</td><td align="left"/></tr><tr><td align="left">&#x000a0;HBs antibody</td><td align="left">(&#x02013;)</td><td align="left"/></tr><tr><td align="left">&#x000a0;IgGHBc antibody</td><td align="left">(&#x02013;)</td><td align="left"/></tr><tr><td align="left">&#x000a0;HCV antibody</td><td align="left">(&#x02013;)</td><td align="left"/></tr><tr><td align="left">Tumor markers</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;AFP</td><td align="left">57.2</td><td align="left">ng/mL</td></tr><tr><td align="left">&#x000a0;AFP-L3</td><td align="left">11.5</td><td align="left">%</td></tr><tr><td align="left">&#x000a0;DCP</td><td align="left">261</td><td align="left">mAU/mL</td></tr><tr><td align="left">&#x000a0;CEA</td><td align="left">4.3</td><td align="left">ng/mL</td></tr><tr><td align="left">&#x000a0;CA19-9</td><td align="left">60.6</td><td align="left">U/mL</td></tr><tr><td align="left">Immunology</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;ANA</td><td align="left">&#x02009;&#x0003c;&#x02009;40</td><td align="left"/></tr><tr><td align="left">&#x000a0;AMA</td><td align="left">&#x02009;&#x0003c;&#x02009;1.5</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>WBC: white blood cells, RBC: red blood cells, Hb: hemoglobin, Ht: hematocrit, Plt: platelet, T-Bil: total bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, &#x003b3;-GTP: gamma-glutamyltransferase, TP: total protein, Alb: albumin, BUN: blood urea nitrogen, Cre: creatinine, CRP:C reactive protein, Na: sodium ion in blood, K:potassium ion in blood, Cl: chlorine ion in blood, BS: blood sugar, HbA1c: hemoglobin A1c, PT: prothrombin, HBs Ag: hepatitis B surface antigen, HBs Ab: hepatitis B surface antibody, HBc Ab: hepatitis B core antibody, HCV Ab: hepatitis C virus antibody, AFP: alpha-fetoprotein, DCP: des-&#x003b3;-carboxy prothrombin, CEA: carcinoembryonic antigen, CA19-9:carbohydrate antigen 19&#x02013;9, ANA: anti-nuclear antibody, AMA: anti-mitochondrial antibody</p></table-wrap-foot></table-wrap></p><p id="Par22">Two weeks after diagnosis, the patient had worsening numbness and pain in both lower extremities at the time of consultation. He was diagnosed as having spinal cord compression syndrome due to a lumbar tumor, and was urgently hospitalized and treated with 39&#x000a0;Gy/13 Fr of radiation and denosumab. After completion of radiotherapy, his symptoms improved, and his AFP, AFP-L3, and DCP levels were confirmed to have decreased (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). On day 28 after completion of radiotherapy, a combination of durvalumab and tremelimumab was started as systemic drug therapy. As of April 202X&#x02009;+&#x02009;2, a total of 11 courses have been administered since the start of treatment, but tumor markers have remained low, and imaging studies have not revealed any new lesions. Contrast CT and PET-CT showed that the lumbar spine tumor had shrunk, SUVmax was 3.3 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), the accumulation was reduced, and the mRECIST CR was maintained for a long period of time. During treatment, adverse events included hypertension, diarrhea, pruritus, and fatigue, all CTCAE (Common Terminology Criteria for Adverse Events) (version5.0) Grade 1, which improved only with symptomatic treatment.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Contrast-enhanced computed tomography (CT) imaging test and Fluorine-18-fluorodeoxyglucose positron emission tomography (FGD-PET) imaging test results before and after treatment. <bold>a</bold>&#x02013;<bold>d</bold> Before RT and durvalumab plus tremelimumab. <bold>e</bold>&#x02013;<bold>h</bold> 9&#x000a0;months after RT and durvalumab plus tremelimumab, 8 courses of durvalumab</p></caption><graphic xlink:href="12328_2024_2044_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Clinical course and trend in tumor markers of the patient. After radiotherapy (39&#x000a0;Gy/13fr) and durvalumab plus tremelimumab administration were started, tumor markers (AFP and DCP) decreased and remained low for a long time</p></caption><graphic xlink:href="12328_2024_2044_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec3"><title>Discussion</title><p id="Par23">Primary liver cancer is the sixth most frequent cancer in the world and the third most common cause of cancer-related death worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. This is a very rare case of HCC arising in the bone without a primary tumor in the liver.</p><p id="Par24">When HCC tissue is found only outside the liver, the differential includes ectopic hepatocellular carcinoma with a primary tumor, hepatoid adenocarcinoma of bone origin, and bone metastasis of HCC without a primary tumor.</p><p id="Par25">Ectopic hepatocellular carcinoma is defined as HCC arising from the liver parenchyma located in extrahepatic organs or tissues [<xref ref-type="bibr" rid="CR3">3</xref>], Some case reports of ectopic hepatocellular carcinoma have been reported in patients without liver diseases such as viral hepatitis or cirrhosis, and the mechanism of carcinogenesis is believed to be different from that of HCC arising in normal sites, which is caused by biliary obstruction or vascular insufficiency of ectopic hepatocytes [<xref ref-type="bibr" rid="CR4">4</xref>]. The sites of ectopic HCC have been reported to include the gallbladder, pancreas, omentum, retroperitoneum, and adrenal glands, and are thought to be most common around the liver and gallbladder [<xref ref-type="bibr" rid="CR5">5</xref>]. Although there have been no reports of ectopic hepatocellular carcinoma arising in bone, a case of hepatocellular carcinoma with a primary site in the thoracic spine was reported based on the finding that bone marrow-derived cells are the origin of hepatocellular carcinoma [<xref ref-type="bibr" rid="CR6">6</xref>]. The possibility that this case is also an ectopic hepatocellular carcinoma with a lumbar spine as the primary site cannot be ruled out.</p><p id="Par26">Hepatoid cell carcinoma is a tumor with features of hepatocellular carcinoma and adenocarcinoma arising in organs other than the liver [<xref ref-type="bibr" rid="CR7">7</xref>]. It is known to occur in various organs, including the stomach, colon, lungs, pancreas, and uterus, but there are no reports of its occurrence in bones [<xref ref-type="bibr" rid="CR8">8</xref>]. In this case, upper and lower gastrointestinal endoscopy revealed no neoplastic lesions in the gastrointestinal tract, and CT showed no neoplastic lesions other than in the lumbar spine. Pathologically, there were no findings suggestive of hepatoid adenocarcinoma, and the possibility of bone-derived hepatoid adenocarcinoma was considered unlikely.</p><p id="Par27">Next, we will discuss the case of a bone lesion being a metastatic lesion of hepatocellular carcinoma. The most common sites of HCC hematogenous extrahepatic metastasis are lungs (55%), abdominal lymph nodes (41%), bones (28%), adrenal glands (11%), and peritoneum (11%) [<xref ref-type="bibr" rid="CR9">9</xref>]. The most common site of bone metastasis of HCC is the spine, followed by the pelvis and ribs [<xref ref-type="bibr" rid="CR10">10</xref>]. In general, extrahepatic metastases usually occur in patients with advanced HCC [<xref ref-type="bibr" rid="CR11">11</xref>]. Case reports of hepatocellular carcinoma with bone metastases but no primary tumor in the liver at the same time are very rare. I found the 15 cases of HCC in bone without a primary lesion in the liver by searching for previous reports. [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>] (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>cases of extrahepatic HCC without a primary lesion in the liver identified by literature search and the our case</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case</th><th align="left">Author</th><th align="left">Year</th><th align="left">Age/sex</th><th align="left">Tumor lesion</th><th align="left">AFP (ng/ml)</th><th align="left">HBs Ag</th><th align="left">HCV Ab</th><th align="left">Diagnostics</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Raoul [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">1995</td><td align="left">58/F</td><td align="left">Skull</td><td align="left">66,000</td><td align="left">(&#x02013;)</td><td align="left">(&#x02013;)</td><td align="left">Operation</td></tr><tr><td align="left">2</td><td align="left">Horita [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">1996</td><td align="left">61/M</td><td align="left">Sternum</td><td align="left">4464</td><td align="left">(&#x02013;)</td><td align="left">(+)</td><td align="left">Operation</td></tr><tr><td align="left">3</td><td align="left">Iosca [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">1998</td><td align="left">71/M</td><td align="left">Lt iliac bone</td><td align="left">Normal</td><td align="left">Untested</td><td align="left">Untested</td><td align="left">Operation</td></tr><tr><td align="left">4</td><td align="left">Asselh [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">2001</td><td align="left">66/M</td><td align="left">Lt chest wall</td><td align="left">Normal</td><td align="left">(&#x02013;)</td><td align="left">(&#x02013;)</td><td align="left">Operation</td></tr><tr><td align="left">5</td><td align="left">Hofmann [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">2003</td><td align="left">61/M</td><td align="left">Rt chest wall</td><td align="left">Normal</td><td align="left">(&#x02013;)</td><td align="left">(&#x02013;)</td><td align="left">Operation</td></tr><tr><td align="left">6</td><td align="left">Coban [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="left">2004</td><td align="left">71/M</td><td align="left">Lt chest wall</td><td align="left">60,000</td><td align="left">(+)</td><td align="left">(&#x02013;)</td><td align="left">Biopsy</td></tr><tr><td align="left">7</td><td align="left">Qureshi [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="left">2005</td><td align="left">50/M</td><td align="left">Sternum</td><td align="left">18,302</td><td align="left">(&#x02013;)</td><td align="left">(&#x02013;)</td><td align="left">Biopsy</td></tr><tr><td align="left">8</td><td align="left">Hyun [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left">2006</td><td align="left">51/M</td><td align="left">Lt chest wall</td><td align="left">308</td><td align="left">(&#x02013;)</td><td align="left">(+)</td><td align="left">Operation</td></tr><tr><td align="left">9</td><td align="left">Khalbuss [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">2007</td><td align="left">62/M</td><td align="left">Lt chest wall</td><td align="left">16,425</td><td align="left">Untested</td><td align="left">Untested</td><td align="left">Aspiration</td></tr><tr><td align="left">10</td><td align="left">Takahama [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left">2010</td><td align="left">63/M</td><td align="left">Lt iliac bone</td><td align="left">114.6</td><td align="left">(&#x02013;)</td><td align="left">(&#x02013;)</td><td align="left">Biopsy</td></tr><tr><td align="left">11</td><td align="left">Jung [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">2012</td><td align="left">74/M</td><td align="left">Rt iliac bone</td><td align="left">Normal</td><td align="left">(+)</td><td align="left">(&#x02013;)</td><td align="left">Biopsy</td></tr><tr><td align="left">12</td><td align="left">Koh [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">2014</td><td align="left">46/M</td><td align="left">Lt chest wall</td><td align="left">292</td><td align="left">(&#x02013;)</td><td align="left">(&#x02013;)</td><td align="left">Biopsy</td></tr><tr><td align="left">13</td><td align="left">Hwamg [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">2015</td><td align="left">61/M</td><td align="left">Cervical spine</td><td align="left">5013.1</td><td align="left">(+)</td><td align="left">(&#x02013;)</td><td align="left">Biopsy</td></tr><tr><td align="left">14</td><td align="left">Abbas [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">2015</td><td align="left">54/M</td><td align="left">iliac bone</td><td align="left">430</td><td align="left">(&#x02013;)</td><td align="left">(+)</td><td align="left">Biopsy</td></tr><tr><td align="left">15</td><td align="left">Shirota [<xref ref-type="bibr" rid="CR6">6</xref>]</td><td align="left">2022</td><td align="left">82/M</td><td align="left">Thoracic spine</td><td align="left">Normal</td><td align="left">(&#x02013;)</td><td align="left">(&#x02013;)</td><td align="left">Biopsy</td></tr><tr><td align="left">16</td><td align="left">Our case</td><td align="left"/><td align="left">58/M</td><td align="left">Lumbar spine</td><td align="left">57.2</td><td align="left">(&#x02013;)</td><td align="left">(&#x02013;)</td><td align="left">Biopsy</td></tr></tbody></table></table-wrap></p><p id="Par28">The absence of a primary tumor in the liver may be due to spontaneous regression of the hepatocellular carcinoma or metastasis from an HCC too small to be detected by imaging studies.</p><p id="Par29">Spontaneous regression of cancer is estimated to occur in 1 case in 60,000 to 100,000 [<xref ref-type="bibr" rid="CR26">26</xref>], and spontaneous regression of HCC is reported to occur in 1.1% to 2.4% of cases. The main mechanisms of spontaneous regression of hepatocellular carcinoma are necrosis due to ischemia and impaired blood circulation and activation of tumor immunity. The former, necrosis due to ischemia and impaired blood circulation, is thought to be caused by secondary nutrient vessel occlusion and poor angiogenesis due to catheterization such as abdominal angiography, damage to the lining of nutrient arteries, circulatory disturbance due to vessel occlusion, massive bleeding, impaired blood flow due to shock, and rapid tumor growth [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The latter activation of tumor immunity has been attributed to the infiltration of inflammatory cells into the tumor, capsule, and surrounding tissues and the associated anti-tumor effects of elevated cytokines such as TNF-&#x003b1;. Triggers that have been cited include external factors such as blood transfusion, trauma, surgery, biopsy, drug involvement, abrupt alcohol cessation, alcoholism, smoking cessation [<xref ref-type="bibr" rid="CR29">29</xref>], etc.</p><p id="Par30">It is also possible that bone metastasis may have developed from HCC of a size that was difficult to detect in imaging studies. In the present case, bone metastasis occurred at the stage of microscopic HCC, which could not be identified by imaging at the time of initial diagnosis, and intrahepatic lesions may have disappeared or spontaneous necrosis may have occurred due to systemic drug therapy.</p><p id="Par31">Treatment options for HCC include hepatectomy or liver transplantation, local therapy, chemoembolization, and systemic pharmacotherapy, but no standard treatment has been established for extrahepatic HCC without a primary tumor. The patient was diagnosed with stage cT0N0M1, cStageIVB, BCLC stage C. According to Western and Japanese guidelines [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], first-line treatment in this situation is systemic drug therapy. Drug therapy includes the use of molecularly targeted agents and immune checkpoint inhibitors alone or in combination. Currently, durvalumab and tremelimumab, atezolizumab and bevacizumab, lenvatinib, and sorafenib are commonly used as first-line therapies for metastatic HCC. The patient underwent radiotherapy (39&#x000a0;Gy/13fr) to palliate symptoms of spinal cord compression due to bone metastasis, followed by systemic drug therapy with durvalumab and tremelimumab according to the guidelines.</p><p id="Par32">The patient has been able to maintain CR for a long period of time, approximately one year, which may have been due to the combination of radiotherapy and ICI. In recent years, it has become clear that irradiation of malignant tumors elicits a specific anti-tumor immune response that enhances therapeutic efficacy. Irradiation of malignant tumors releases an immunostimulatory protein (HMGB1), which activates dendritic cells. In addition, T cells are activated when dead cancer cells are recognized and presented as cancer antigens through phagocytosis by dendritic cells [<xref ref-type="bibr" rid="CR32">32</xref>]. The PD-1 receptor is an immune checkpoint receptor expressed on the surface of activated T cells that induces peripheral immune tolerance by binding to PD-L1 [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Radiation induces PD-L1 expression in cancer cells and immune tolerance. This indicates that irradiation activates anti-tumor immunity, while at the same time the tumor reinforces immune escape mechanisms [<xref ref-type="bibr" rid="CR32">32</xref>]. Thus, the combination of radiotherapy and PD-1/PD-L1 inhibitors is expected to enhance the therapeutic effect. On the other hand, CTLA-4 is an immune mechanism regulatory molecule expressed on the surface of activated T cells and constitutes an inhibitory pathway called the immune checkpoint; blocking CTLA-4 has been reported to enhance antitumor immunity [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Based on the above, we believe that the combination of radiotherapy and the immune checkpoint inhibitors durvalumab and tremelimumab has suppressed tumor growth and maintained CR over the long term.</p></sec><sec id="Sec4"><title>Conclusion</title><p id="Par33">We have experienced a case of HCC in the lumbar spine without a primary tumor in the liver. This is a very rare case, and the combination of durvalumab and tremelimumab resulted in a complete response, making this a valuable case. In addition, the combination of radiotherapy and immune checkpoint inhibition may be useful in enhancing the therapeutic effect.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HCC</term><def><p id="Par2">Hepatocellular carcinoma</p></def></def-item><def-item><term>AFP</term><def><p id="Par3">&#x003b1;-Fetoprotein</p></def></def-item><def-item><term>DCP</term><def><p id="Par4"><italic>des</italic>-&#x003b3;-Carboxy prothrombin</p></def></def-item><def-item><term>HBV</term><def><p id="Par5">Hepatitis B virus</p></def></def-item><def-item><term>HCV</term><def><p id="Par6">Hepatitis C virus</p></def></def-item><def-item><term>NBNC</term><def><p id="Par7">Non-hepatitis B virus, non-hepatitis C virus</p></def></def-item><def-item><term>ICI</term><def><p id="Par8">Immune checkpoint inhibitor</p></def></def-item><def-item><term>CT</term><def><p id="Par9">Computed tomography</p></def></def-item><def-item><term>MRI</term><def><p id="Par10">Magnetic resonance imaging</p></def></def-item><def-item><term>PET-CT</term><def><p id="Par11">Positron emission tomography&#x02013;computed tomography</p></def></def-item><def-item><term>SUV</term><def><p id="Par12">Standardized uptake value</p></def></def-item><def-item><term>BCLC</term><def><p id="Par13">Barcelona Clinic Liver Cancer</p></def></def-item><def-item><term>RECIST</term><def><p id="Par14">Response Evaluation Criteria in Solid Tumors</p></def></def-item><def-item><term>CR</term><def><p id="Par15">Complete response</p></def></def-item><def-item><term>CTCAE</term><def><p id="Par16">Common Terminology Criteria for Adverse Events</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided by Hiroshima University.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par34">Tomokazu Kawaoka received honoraria (lecture fees) from Chugai Pharmaceutical Co., Ltd and AstraZeneca PLC.</p></notes><notes id="FPar2"><title>Ethics statement</title><p id="Par35">This study was conducted in accordance with the ethics principles of the Declaration of Helsinki.</p></notes><notes id="FPar3"><title>Informed consent</title><p id="Par36">Informed consent was obtained from patient in this study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization International Agency for Research on Cancer. <ext-link ext-link-type="uri" xlink:href="http://globocan.iarc.fr/">http://globocan.iarc.fr/</ext-link>.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Formenti</surname><given-names>S</given-names></name></person-group><article-title>Current clinical trials testing the combination of immunotherapy with radiotherapy</article-title><source>J Immunother Cancer</source><year>2016</year><volume>4</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s40425-016-0156-7</pub-id><pub-id pub-id-type="pmid">27660705</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51.<pub-id pub-id-type="pmid">27660705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name></person-group><article-title>Ectopic hepatocellular carcinoma manifesting multiple abdominal masses</article-title><source>Medicine</source><year>2017</year><volume>96</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000008968</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Jin R, Yu Q, Liang X. Ectopic hepatocellular carcinoma manifesting multiple abdominal masses. Medicine. 2017;96:48.</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Yusa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Ectopic hepatocellular carcinoma mimicking a retroperitoneal tumor: a case report</article-title><source>World J Gastroenterol</source><year>2020</year><volume>26</volume><issue>18</issue><fpage>2268</fpage><lpage>2275</lpage><pub-id pub-id-type="doi">10.3748/wjg.v26.i18.2268</pub-id><pub-id pub-id-type="pmid">32476791</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Adachi Y, Hayashi H, Yusa T, et al. Ectopic hepatocellular carcinoma mimicking a retroperitoneal tumor: a case report. World J Gastroenterol. 2020;26(18):2268&#x02013;75.<pub-id pub-id-type="pmid">32476791</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name></person-group><article-title>Ectopic hepatocellular carcinoma in the gallbladder wall with choledocholithiasis</article-title><source>Cureus</source><year>2023</year><pub-id pub-id-type="doi">10.7759/cureus.49534</pub-id><pub-id pub-id-type="pmid">38269227</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Nakajima T, Tsukamoto T. Ectopic hepatocellular carcinoma in the gallbladder wall with choledocholithiasis. Cureus. 2023. 10.7759/cureus.49534.<pub-id pub-id-type="pmid">38269227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Shirota</surname><given-names>Y</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><etal/></person-group><article-title>Solitary extrahepatic hepatocellular carcinoma in vertebrae without a primary lesion in the liver might originate from bone marrow: a case report and new hypothesis based on a review of the literature and the latest findings</article-title><source>Clin J Gastroenterol</source><year>2022</year><volume>15</volume><issue>6</issue><fpage>1115</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1007/s12328-022-01701-w</pub-id><pub-id pub-id-type="pmid">36109475</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Shirota Y, Ueda Y, Sato K, et al. Solitary extrahepatic hepatocellular carcinoma in vertebrae without a primary lesion in the liver might originate from bone marrow: a case report and new hypothesis based on a review of the literature and the latest findings. Clin J Gastroenterol. 2022;15(6):1115&#x02013;23.<pub-id pub-id-type="pmid">36109475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>WK</given-names></name><name><surname>Cho</surname><given-names>DH</given-names></name><name><surname>Yim</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Primary hepatoid carcinoma of the ovary: a case report and review of the literature</article-title><source>Medicine (Baltimore)</source><year>2020</year><volume>99</volume><issue>19</issue><fpage>e20051</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000020051</pub-id><pub-id pub-id-type="pmid">32384467</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Choi WK, Cho DH, Yim CY, et al. Primary hepatoid carcinoma of the ovary: a case report and review of the literature. Medicine (Baltimore). 2020;99(19): e20051. 10.1097/MD.0000000000020051.<pub-id pub-id-type="pmid">32384467</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Gakiopoulou</surname><given-names>H</given-names></name><name><surname>Givalos</surname><given-names>N</given-names></name><name><surname>Liapis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Hepatoid adenocarcinoma of the gallbladder</article-title><source>Dig Dis Sci</source><year>2007</year><volume>52</volume><fpage>3358</fpage><lpage>3362</lpage><pub-id pub-id-type="doi">10.1007/s10620-007-9807-3</pub-id><pub-id pub-id-type="pmid">17510803</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gakiopoulou H, Givalos N, Liapis G, et al. Hepatoid adenocarcinoma of the gallbladder. Dig Dis Sci. 2007;52:3358&#x02013;62.<pub-id pub-id-type="pmid">17510803</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Katyal</surname><given-names>S</given-names></name><name><surname>Oliver</surname><given-names>JH</given-names><suffix>3rd</suffix></name><name><surname>Peterson</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Extrahepatic metastases of hepatocellular carcinoma</article-title><source>Radiology</source><year>2000</year><volume>216</volume><issue>3</issue><fpage>698</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1148/radiology.216.3.r00se24698</pub-id><pub-id pub-id-type="pmid">10966697</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216(3):698&#x02013;703.<pub-id pub-id-type="pmid">10966697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukutomi</surname><given-names>M</given-names></name><name><surname>Yokota</surname><given-names>M</given-names></name><name><surname>Chuman</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increased incidence of bone metastases in hepatocellular carcinoma</article-title><source>Eur J Gastroenterol Hepatol</source><year>2001</year><volume>13</volume><issue>9</issue><fpage>1083</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1097/00042737-200109000-00015</pub-id><pub-id pub-id-type="pmid">11564960</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Fukutomi M, Yokota M, Chuman H, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2001;13(9):1083&#x02013;8.<pub-id pub-id-type="pmid">11564960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Kummar</surname><given-names>S</given-names></name><name><surname>Shafi</surname><given-names>NQ</given-names></name></person-group><article-title>Metastatic hepatocellular carcinoma</article-title><source>Clin Oncol</source><year>2003</year><volume>15</volume><fpage>288</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/S0936-6555(03)00067-0</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kummar S, Shafi NQ. Metastatic hepatocellular carcinoma. Clin Oncol. 2003;15:288&#x02013;94. 10.1016/S0936-6555(03)00067-0.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Raoul</surname><given-names>L</given-names></name><name><surname>Le Simple</surname><given-names>T</given-names></name><name><surname>Le Pris&#x000e9;</surname><given-names>E</given-names></name><etal/></person-group><article-title>Bone metastasis revealing hepatocellular carcinoma: a report of three cases with a long clinical course</article-title><source>Am J Gastroenterol</source><year>1995</year><volume>90</volume><fpage>1162</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">7611219</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Raoul L, Le Simple T, Le Pris&#x000e9; E, et al. Bone metastasis revealing hepatocellular carcinoma: a report of three cases with a long clinical course. Am J Gastroenterol. 1995;90:1162&#x02013;4.<pub-id pub-id-type="pmid">7611219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Horita</surname><given-names>K</given-names></name><name><surname>Okazaki</surname><given-names>Y</given-names></name><name><surname>Haraguchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>A case of solitary sternal metastasis from unknown primary hepatocellular carcinoma</article-title><source>Nihon Kyobu Geka Gakkai Zasshi</source><year>1996</year><volume>44</volume><fpage>959</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">8741556</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Horita K, Okazaki Y, Haraguchi A, et al. A case of solitary sternal metastasis from unknown primary hepatocellular carcinoma. Nihon Kyobu Geka Gakkai Zasshi. 1996;44:959&#x02013;64.<pub-id pub-id-type="pmid">8741556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Iosca</surname><given-names>A</given-names></name><name><surname>Spaggiari</surname><given-names>L</given-names></name><name><surname>Pierfranco</surname><given-names>SP</given-names></name></person-group><article-title>A bone hepatocellular carcinoma metastasis without hepatic tumor: a long-term follow-up</article-title><source>Am J Gastroenterol</source><year>1998</year><volume>93</volume><fpage>663</fpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.1998.663_b.x</pub-id><pub-id pub-id-type="pmid">9576474</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Iosca A, Spaggiari L, Pierfranco SP. A bone hepatocellular carcinoma metastasis without hepatic tumor: a long-term follow-up. Am J Gastroenterol. 1998;93:663.<pub-id pub-id-type="pmid">9576474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Asselah</surname><given-names>T</given-names></name><name><surname>Condat</surname><given-names>B</given-names></name><name><surname>Cazals-Hatem</surname><given-names>D</given-names></name><etal/></person-group><article-title>Ectopic hepatocellular carcinoma arising in the left chest wall: a long-term follow-up</article-title><source>Eur J Gastroenterol Hepatol</source><year>2001</year><volume>13</volume><fpage>873</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1097/00042737-200107000-00018</pub-id><pub-id pub-id-type="pmid">11474320</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Asselah T, Condat B, Cazals-Hatem D, et al. Ectopic hepatocellular carcinoma arising in the left chest wall: a long-term follow-up. Eur J Gastroenterol Hepatol. 2001;13:873&#x02013;5. 10.1097/00042737-200107000-00018.<pub-id pub-id-type="pmid">11474320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>H-S</given-names></name><name><surname>Spillner</surname><given-names>J</given-names></name><name><surname>Hammer</surname><given-names>A</given-names></name><etal/></person-group><article-title>A solitary chest wall metastasis from unknown primary hepatocellular carcinoma</article-title><source>Eur J Gastroenterol Hepatol</source><year>2003</year><volume>15</volume><issue>5</issue><fpage>557</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1097/01.meg.0000059105.41030.55</pub-id><pub-id pub-id-type="pmid">12702916</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Hofmann H-S, Spillner J, Hammer A, et al. A solitary chest wall metastasis from unknown primary hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2003;15(5):557&#x02013;9. 10.1097/01.meg.0000059105.41030.55.<pub-id pub-id-type="pmid">12702916</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c7;oban</surname><given-names>&#x0015e;</given-names></name><name><surname>Y&#x000fc;ksel</surname><given-names>O</given-names></name><name><surname>K&#x000f6;kl&#x000fc;</surname><given-names>S</given-names></name><etal/></person-group><article-title>Atypical presentation of hepatocellular carcinoma: a mass on the left thoracic wall</article-title><source>BMC Cancer</source><year>2004</year><volume>4</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-4-89</pub-id><pub-id pub-id-type="pmid">15574203</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">&#x000c7;oban &#x0015e;, Y&#x000fc;ksel O, K&#x000f6;kl&#x000fc; S, et al. Atypical presentation of hepatocellular carcinoma: a mass on the left thoracic wall. BMC Cancer. 2004;4:89. 10.1186/1471-2407-4-89.<pub-id pub-id-type="pmid">15574203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>SS</given-names></name><name><surname>Shrikhande</surname><given-names>SV</given-names></name><name><surname>Borges</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Chest wall metastases from unknown primary hepatocellular carcinoma</article-title><source>J Postgrad Med</source><year>2005</year><volume>51</volume><fpage>41</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15793338</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Qureshi SS, Shrikhande SV, Borges AM, et al. Chest wall metastases from unknown primary hepatocellular carcinoma. J Postgrad Med. 2005;51:41&#x02013;2.<pub-id pub-id-type="pmid">15793338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>YS</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name><name><surname>Bae</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Chest wall metastasis from unknown primary site of hepatocellular carcinoma</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>2139</fpage><lpage>2142</lpage><pub-id pub-id-type="doi">10.3748/wjg.v12.i13.2139</pub-id><pub-id pub-id-type="pmid">16610073</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hyun YS, Choi HS, Bae JH, et al. Chest wall metastasis from unknown primary site of hepatocellular carcinoma. World J Gastroenterol. 2006;12:2139&#x02013;42.<pub-id pub-id-type="pmid">16610073</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Khalbuss</surname><given-names>WE</given-names></name><name><surname>Bajestani</surname><given-names>S</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>HJ</given-names></name></person-group><article-title>Cytomorphology of a solitary left chest wall mass: an unusual presentation from unknown primary hepatocellular carcinoma</article-title><source>Diagn Cytopathol</source><year>2007</year><volume>35</volume><fpage>586</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1002/dc.20459</pub-id><pub-id pub-id-type="pmid">17703451</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Khalbuss WE, Bajestani S, D&#x02019;Agostino HJ. Cytomorphology of a solitary left chest wall mass: an unusual presentation from unknown primary hepatocellular carcinoma. Diagn Cytopathol. 2007;35:586&#x02013;9.<pub-id pub-id-type="pmid">17703451</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahama</surname><given-names>J</given-names></name><name><surname>Taoka</surname><given-names>T</given-names></name><name><surname>Marugami</surname><given-names>N</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma of the iliac bone with unknown primary</article-title><source>Skeletal Radiol</source><year>2010</year><volume>39</volume><fpage>721</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1007/s00256-010-0891-7</pub-id><pub-id pub-id-type="pmid">20162272</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Takahama J, Taoka T, Marugami N, et al. Hepatocellular carcinoma of the iliac bone with unknown primary. Skeletal Radiol. 2010;39:721&#x02013;4.<pub-id pub-id-type="pmid">20162272</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>KS</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>Chon</surname><given-names>YE</given-names></name><etal/></person-group><article-title>A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone</article-title><source>Korean J Hepatol</source><year>2012</year><volume>18</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.3350/kjhep.2012.18.1.89</pub-id><pub-id pub-id-type="pmid">22511908</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Jung KS, Park KH, Chon YE, et al. A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone. Korean J Hepatol. 2012;18:89&#x02013;93.<pub-id pub-id-type="pmid">22511908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>PS</given-names></name><name><surname>Yusof</surname><given-names>MM</given-names></name><name><surname>Yoong</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Mediastinal hepatocellular carcinoma with unknown primary: an unusual and rare presentation</article-title><source>J Gastrointest Cancer</source><year>2014</year><volume>45</volume><issue>Suppl 1</issue><fpage>74</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1007/s12029-013-9549-8</pub-id><pub-id pub-id-type="pmid">24045908</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Koh PS, Yusof MM, Yoong BK, et al. Mediastinal hepatocellular carcinoma with unknown primary: an unusual and rare presentation. J Gastrointest Cancer. 2014;45(Suppl 1):74&#x02013;6.<pub-id pub-id-type="pmid">24045908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma with cervical spine and pelvic bone metastases presenting as unknown primary neoplasm</article-title><source>Korean J Gastroenterol</source><year>2015</year><volume>66</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.4166/kjg.2015.66.1.50</pub-id><pub-id pub-id-type="pmid">26194130</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Hwang SW, Lee JE, Lee JM, et al. Hepatocellular carcinoma with cervical spine and pelvic bone metastases presenting as unknown primary neoplasm. Korean J Gastroenterol. 2015;66:50&#x02013;4.<pub-id pub-id-type="pmid">26194130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>SH</given-names></name><name><surname>Khan</surname><given-names>MZ</given-names></name><name><surname>Ijaz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metastatic hepatocellular carcinoma to the pelvis and vertebrae in a patient with chronic hepatitis &#x02018;C&#x02019; with unknown primary</article-title><source>BMJ Case Rep</source><year>2015</year><pub-id pub-id-type="doi">10.1136/bcr-2014-207249</pub-id><pub-id pub-id-type="pmid">25935910</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Abbas SH, Khan MZ, Ijaz M, et al. Metastatic hepatocellular carcinoma to the pelvis and vertebrae in a patient with chronic hepatitis &#x02018;C&#x02019; with unknown primary. BMJ Case Rep. 2015. 10.1136/bcr-2014-207249.<pub-id pub-id-type="pmid">25935910</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>WH</given-names></name></person-group><article-title>Efforts to explain spontaneous regression of cancer</article-title><source>J Surg Oncol</source><year>1981</year><volume>17</volume><issue>3</issue><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1002/jso.2930170302</pub-id><pub-id pub-id-type="pmid">6166811</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17(3):201&#x02013;9. 10.1002/jso.2930170302.<pub-id pub-id-type="pmid">6166811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Okazaki</surname><given-names>N</given-names></name><name><surname>Yoshino</surname><given-names>M</given-names></name><etal/></person-group><article-title>Spontaneous regression of a hepatocellular carcinoma&#x02013;a case report</article-title><source>Hepatogastroenterology</source><year>1989</year><volume>36</volume><issue>3</issue><fpage>160</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">2546879</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Suzuki M, Okazaki N, Yoshino M, et al. Spontaneous regression of a hepatocellular carcinoma&#x02013;a case report. Hepatogastroenterology. 1989;36(3):160&#x02013;3.<pub-id pub-id-type="pmid">2546879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Imaoka</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Masutani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Necrosis of hepatocellular carcinoma caused by spontaneously arising arterial thrombus</article-title><source>Hepatogastroenterology</source><year>1994</year><volume>41</volume><issue>4</issue><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">7525432</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Imaoka S, Sasaki Y, Masutani S, et al. Necrosis of hepatocellular carcinoma caused by spontaneously arising arterial thrombus. Hepatogastroenterology. 1994;41(4):359&#x02013;62.<pub-id pub-id-type="pmid">7525432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Wakui</surname><given-names>N</given-names></name><name><surname>Asai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Spontaneous complete necrosis of hepatocellular carcinoma: a case report and review of the literature</article-title><source>Oncol Lett</source><year>2015</year><volume>9</volume><issue>4</issue><fpage>1520</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.3892/ol.2015.2937</pub-id><pub-id pub-id-type="pmid">25788993</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Takeda Y, Wakui N, Asai Y, et al. Spontaneous complete necrosis of hepatocellular carcinoma: a case report and review of the literature. Oncol Lett. 2015;9(4):1520&#x02013;6. 10.3892/ol.2015.2937.<pub-id pub-id-type="pmid">25788993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Piscaglia</surname><given-names>F</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Schirmacher</surname><given-names>P</given-names></name><name><surname>Vilgrain</surname><given-names>V</given-names></name></person-group><article-title>EASL clinical practice guidelines: management of hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><issue>1</issue><fpage>182</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.019</pub-id><pub-id pub-id-type="pmid">29628281</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182&#x02013;236.<pub-id pub-id-type="pmid">29628281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Group formed to establish "Guidelines for evidence-based clinical practice for the treatment of liver cancer"; Japan Society of Hepatology. Clinical practice guidelines for hepatocellular carcinoma (2021 version). Kanehara, Tokyo, Japan, 2021. (<bold>in Japanese</bold>)</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Niimi</surname><given-names>A</given-names></name><name><surname>Yasuhara</surname><given-names>T</given-names></name><etal/></person-group><article-title>DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><issue>1</issue><fpage>1751</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01883</pub-id><pub-id pub-id-type="pmid">29170499</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8(1):1751. 10.1038/s41467-017-01883.<pub-id pub-id-type="pmid">29170499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Intlekofer</surname><given-names>AM</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><article-title>At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy</article-title><source>J Leukoc Biol</source><year>2013</year><volume>94</volume><issue>1</issue><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1189/jlb.1212621</pub-id><pub-id pub-id-type="pmid">23625198</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25&#x02013;39.<pub-id pub-id-type="pmid">23625198</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name></person-group><article-title>At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy</article-title><source>J Leukoc Biol</source><year>2013</year><volume>94</volume><issue>1</issue><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1189/jlb.1212631</pub-id><pub-id pub-id-type="pmid">23667165</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94(1):41&#x02013;53. 10.1189/jlb.1212631.<pub-id pub-id-type="pmid">23667165</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>